CHAIKIN MONEY FLOW
Trading: SELL @ $0.46
Signal Strength: MEDIUM
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Bionomics (ASX:BNO) current price has highlighted recent selling pressure and the continuation of a bearish trading conditions. Currently, the CMF is -0.2. BNO.AXThe bearish signal has been active for 0 day. During the quarter, the lowest CMF value was -0.29 occurring on the Jul 26 2018.
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;
PROFILE: Bionomics (BNO.AX)
Stock Exchange: ASX
Ticker Codes: | BNO.AX | ASX:BNO |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
|Company||Close||Close Change (%)||Volume||Value||Signal|
|OCL Objective Corporation||2.92||6.6||24,050||-0.29||BEARISH|
|GSC Global Geoscience||0.27||6||3,421,603||-0.11||BEARISH|
|CVW Clearview Wealth||1.1||4.8||19,003||-0.31||BEARISH|
|MNF My Net Fone||5.65||4.6||72,693||-0.3||BEARISH|
|MCY Mighty River Power||3.15||4.3||757||-0.7||BEARISH|